Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Change in Receivables (2020 - 2025)

Rani Therapeutics Holdings has reported Change in Receivables over the past 2 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Change in Receivables at $2.5 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $2.0 million (changed N/A YoY), and the annual figure for FY2025 was $2.0 million, changed.
  • Change in Receivables for Q4 2025 was $2.5 million at Rani Therapeutics Holdings, up from -$1.0 million in the prior quarter.
  • Over the last five years, Change in Receivables for RANI hit a ceiling of $2.5 million in Q4 2025 and a floor of -$1.0 million in Q2 2025.